Skip to main content
. Author manuscript; available in PMC: 2020 Sep 1.
Published in final edited form as: Cancer. 2019 May 8;125(17):3013–3024. doi: 10.1002/cncr.32162

Figure 4.

Figure 4.

Kaplan Meier Estimates of Melanoma Specific Survival (MSS) for Patients Treated on A) E1690: HR = 0.97 [95% CI: 0.74, 1.28], B) E1694: HR = 0.79 [95% CI: 0.63,0.98] and C) E2696 HR (concurrent vs. GMK alone) = 1.18 [95% CI: 0.57, 2.42], HR (sequential vs. GMK alone) = 0.82 [95% CI: 0.38, 1.78].